newswire, breaking biotechnology and pharma news

Friday, December 30, 2011

Biotech /Pharma Stock Trading Alert: Antares (NYSE Amex: AIS) Moves Up 30% From December 15th Lows

December 15th; “Antares Sell-Off is a Holiday Gift”- Josh Levine  

Point Roberts, WA- December 30 , 2011-, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert and updated commentary from Josh Levine of the Levine MicroCap Newsletter, for Antares Pharma, Inc. (NYSE Amex: AIS).

The stock is trading at $2.20, up strongly from its sell off and low of $1.51 on December 15th, following news from partner BioSante Pharmaceuticals.

Following up his comments about AIS on December 15, Josh Levine said today: “Antares has surged 30% in two weeks and is again trading above its 200-day moving average. The market quickly and correctly recognized that the LibiGel event does nothing to tarnish the company’s outlook, which has never been stronger.”

December 15th- “Antares Sell-Off is a Holiday Gift”- Josh Levine -

“After the market close yesterday, Antares Pharma (AIS) partner Biosante reported results from two Phase III efficacy trials for Libigel, which is used to treat hypoactive sexual desire disorder in post-menopausal women. Here’s the bottom line: While Libigel was extremely effective and reinforced previous studies, the placebo group fared nearly as well. The failure appears to have been due to a surprisingly high placebo effect. The impact on Biosante is devastating, but it’s only a minor bump in the road for Antares. Today’s 30%-plus drop in AIS shares is an overreaction and the stock will rebound fully in time.”

He also noted, “Libigel, if successful, would have only begun contributing revenues to Antares in 2015.”

About Josh Levine and Levine's MicroCap Investor
Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks.

About Antares Pharma, Inc. (NYSE Amex: AIS)
Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include VIBEX™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Anturol® gel, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares’ partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® estradiol gel indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.

Get biotech news and stock alerts

Research more biotech stocks at the Biotech stocks Directory:

About is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow on Twitter!/Investorideas
Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure. BPAX compensates investorideas .com for news release dissemination and content creation. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source –

No comments:

Post a Comment